메뉴 건너뛰기




Volumn 24, Issue 1, 2016, Pages 15-30

The Cardiovascular Biology of Glucagon-like Peptide-1

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; INCRETIN;

EID: 84992358035     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2016.06.009     Document Type: Review
Times cited : (482)

References (131)
  • 2
    • 77951151612 scopus 로고    scopus 로고
    • Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4
    • Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., Watada, H., Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59 (2010), 1030–1037.
    • (2010) Diabetes , vol.59 , pp. 1030-1037
    • Arakawa, M.1    Mita, T.2    Azuma, K.3    Ebato, C.4    Goto, H.5    Nomiyama, T.6    Fujitani, Y.7    Hirose, T.8    Kawamori, R.9    Watada, H.10
  • 3
    • 84939540746 scopus 로고    scopus 로고
    • Cardioprotection resulting from glucagon-like peptide-1 administration involves shifting metabolic substrate utilization to increase energy efficiency in the rat heart
    • Aravindhan, K., Bao, W., Harpel, M.R., Willette, R.N., Lepore, J.J., Jucker, B.M., Cardioprotection resulting from glucagon-like peptide-1 administration involves shifting metabolic substrate utilization to increase energy efficiency in the rat heart. PLoS ONE, 10, 2015, e0130894.
    • (2015) PLoS ONE , vol.10 , pp. e0130894
    • Aravindhan, K.1    Bao, W.2    Harpel, M.R.3    Willette, R.N.4    Lepore, J.J.5    Jucker, B.M.6
  • 4
    • 84957840942 scopus 로고    scopus 로고
    • Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
    • Armstrong, M.J., Gaunt, P., Aithal, G.P., Barton, D., Hull, D., Parker, R., Hazlehurst, J.M., Guo, K., Abouda, G., Aldersley, M.A., et al., LEAN trial team. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387 (2016), 679–690.
    • (2016) Lancet , vol.387 , pp. 679-690
    • Armstrong, M.J.1    Gaunt, P.2    Aithal, G.P.3    Barton, D.4    Hull, D.5    Parker, R.6    Hazlehurst, J.M.7    Guo, K.8    Abouda, G.9    Aldersley, M.A.10
  • 5
    • 84960521846 scopus 로고    scopus 로고
    • 5. Glycemic targets
    • American Diabetes Association. 5. Glycemic targets. Diabetes Care 39:Suppl 1 (2016), S39–S46.
    • (2016) Diabetes Care , vol.39 , pp. S39-S46
  • 7
    • 43249089631 scopus 로고    scopus 로고
    • Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
    • Ban, K., Noyan-Ashraf, M.H., Hoefer, J., Bolz, S.S., Drucker, D.J., Husain, M., Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117 (2008), 2340–2350.
    • (2008) Circulation , vol.117 , pp. 2340-2350
    • Ban, K.1    Noyan-Ashraf, M.H.2    Hoefer, J.3    Bolz, S.S.4    Drucker, D.J.5    Husain, M.6
  • 8
    • 77950267745 scopus 로고    scopus 로고
    • Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor
    • Ban, K., Kim, K.H., Cho, C.K., Sauvé, M., Diamandis, E.P., Backx, P.H., Drucker, D.J., Husain, M., Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 151 (2010), 1520–1531.
    • (2010) Endocrinology , vol.151 , pp. 1520-1531
    • Ban, K.1    Kim, K.H.2    Cho, C.K.3    Sauvé, M.4    Diamandis, E.P.5    Backx, P.H.6    Drucker, D.J.7    Husain, M.8
  • 11
    • 84954306378 scopus 로고    scopus 로고
    • Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner
    • Bułdak, Ł., Machnik, G., Bułdak, R.J., Łabuzek, K., Bołdys, A., Belowski, D., Basiak, M., Okopień, B., Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner. Pharmacol. Rep. 68 (2016), 329–337.
    • (2016) Pharmacol. Rep. , vol.68 , pp. 329-337
    • Bułdak, Ł.1    Machnik, G.2    Bułdak, R.J.3    Łabuzek, K.4    Bołdys, A.5    Belowski, D.6    Basiak, M.7    Okopień, B.8
  • 14
    • 84878808238 scopus 로고    scopus 로고
    • Pharmacology, physiology, and mechanisms of incretin hormone action
    • Campbell, J.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17 (2013), 819–837.
    • (2013) Cell Metab. , vol.17 , pp. 819-837
    • Campbell, J.E.1    Drucker, D.J.2
  • 15
    • 84879783953 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes
    • Ceriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., Genovese, S., Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care 36 (2013), 2346–2350.
    • (2013) Diabetes Care , vol.36 , pp. 2346-2350
    • Ceriello, A.1    Novials, A.2    Ortega, E.3    Canivell, S.4    La Sala, L.5    Pujadas, G.6    Esposito, K.7    Giugliano, D.8    Genovese, S.9
  • 17
    • 84897834466 scopus 로고    scopus 로고
    • Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: a potential confounding factor in the nonclinical assessment of GLP-1-based therapies
    • Chadwick, K.D., Fletcher, A.M., Parrula, M.C., Bonner-Weir, S., Mangipudy, R.S., Janovitz, E., Graziano, M.J., Roy, D., Reilly, T.P., Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: a potential confounding factor in the nonclinical assessment of GLP-1-based therapies. Diabetes 63 (2014), 1303–1314.
    • (2014) Diabetes , vol.63 , pp. 1303-1314
    • Chadwick, K.D.1    Fletcher, A.M.2    Parrula, M.C.3    Bonner-Weir, S.4    Mangipudy, R.S.5    Janovitz, E.6    Graziano, M.J.7    Roy, D.8    Reilly, T.P.9
  • 19
    • 84954235632 scopus 로고    scopus 로고
    • Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
    • Chen, W.R., Hu, S.Y., Chen, Y.D., Zhang, Y., Qian, G., Wang, J., Yang, J.J., Wang, Z.F., Tian, F., Ning, Q.X., Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am. Heart J. 170 (2015), 845–854.
    • (2015) Am. Heart J. , vol.170 , pp. 845-854
    • Chen, W.R.1    Hu, S.Y.2    Chen, Y.D.3    Zhang, Y.4    Qian, G.5    Wang, J.6    Yang, J.J.7    Wang, Z.F.8    Tian, F.9    Ning, Q.X.10
  • 20
    • 84908501502 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 receptor agonist activation ameliorates venous thrombosis-induced arteriovenous fistula failure in chronic kidney disease
    • Chien, C.T., Fan, S.C., Lin, S.C., Kuo, C.C., Yang, C.H., Yu, T.Y., Lee, S.P., Cheng, D.Y., Li, P.C., Glucagon-like peptide-1 receptor agonist activation ameliorates venous thrombosis-induced arteriovenous fistula failure in chronic kidney disease. Thromb. Haemost. 112 (2014), 1051–1064.
    • (2014) Thromb. Haemost. , vol.112 , pp. 1051-1064
    • Chien, C.T.1    Fan, S.C.2    Lin, S.C.3    Kuo, C.C.4    Yang, C.H.5    Yu, T.Y.6    Lee, S.P.7    Cheng, D.Y.8    Li, P.C.9
  • 21
    • 84959481026 scopus 로고    scopus 로고
    • Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
    • Dejgaard, T.F., Frandsen, C.S., Hansen, T.S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A.K., Holst, J.J., Tarnow, L., et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 4 (2016), 221–232.
    • (2016) Lancet Diabetes Endocrinol. , vol.4 , pp. 221-232
    • Dejgaard, T.F.1    Frandsen, C.S.2    Hansen, T.S.3    Almdal, T.4    Urhammer, S.5    Pedersen-Bjergaard, U.6    Jensen, T.7    Jensen, A.K.8    Holst, J.J.9    Tarnow, L.10
  • 22
    • 84937006493 scopus 로고    scopus 로고
    • Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm
    • Devin, J.K., Pretorius, M., Nian, H., Yu, C., Billings, F.T. 4th, Brown, N.J., Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm. J. Am. Heart Assoc., 3, 2014, 10.1161/JAHA.114.001075.
    • (2014) J. Am. Heart Assoc. , vol.3
    • Devin, J.K.1    Pretorius, M.2    Nian, H.3    Yu, C.4    Billings, F.T.5    Brown, N.J.6
  • 23
    • 84901920026 scopus 로고    scopus 로고
    • Targeting inflammation in the treatment of type 2 diabetes: time to start
    • Donath, M.Y., Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat. Rev. Drug Discov. 13 (2014), 465–476.
    • (2014) Nat. Rev. Drug Discov. , vol.13 , pp. 465-476
    • Donath, M.Y.1
  • 24
    • 33644618433 scopus 로고    scopus 로고
    • The biology of incretin hormones
    • Drucker, D.J., The biology of incretin hormones. Cell Metab. 3 (2006), 153–165.
    • (2006) Cell Metab. , vol.3 , pp. 153-165
    • Drucker, D.J.1
  • 25
    • 84884583757 scopus 로고    scopus 로고
    • Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls
    • Drucker, D.J., Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 62 (2013), 3316–3323.
    • (2013) Diabetes , vol.62 , pp. 3316-3323
    • Drucker, D.J.1
  • 26
    • 84921915993 scopus 로고    scopus 로고
    • Deciphering metabolic messages from the gut drives therapeutic innovation: the 2014 Banting Lecture
    • Drucker, D.J., Deciphering metabolic messages from the gut drives therapeutic innovation: the 2014 Banting Lecture. Diabetes 64 (2015), 317–326.
    • (2015) Diabetes , vol.64 , pp. 317-326
    • Drucker, D.J.1
  • 27
    • 84960876649 scopus 로고    scopus 로고
    • Evolving concepts and translational relevance of enteroendocrine cell biology
    • Drucker, D.J., Evolving concepts and translational relevance of enteroendocrine cell biology. J. Clin. Endocrinol. Metab. 101 (2016), 778–786.
    • (2016) J. Clin. Endocrinol. Metab. , vol.101 , pp. 778-786
    • Drucker, D.J.1
  • 28
    • 33846006173 scopus 로고    scopus 로고
    • The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
    • Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
    • (2006) Lancet , vol.368 , pp. 1696-1705
    • Drucker, D.J.1    Nauck, M.A.2
  • 29
    • 80054708816 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology
    • Drucker, D.J., Rosen, C.F., Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology. Diabetologia 54 (2011), 2741–2744.
    • (2011) Diabetologia , vol.54 , pp. 2741-2744
    • Drucker, D.J.1    Rosen, C.F.2
  • 31
    • 84908177336 scopus 로고    scopus 로고
    • Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
    • Dungan, K.M., Povedano, S.T., Forst, T., González, J.G., Atisso, C., Sealls, W., Fahrbach, J.L., Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 384 (2014), 1349–1357.
    • (2014) Lancet , vol.384 , pp. 1349-1357
    • Dungan, K.M.1    Povedano, S.T.2    Forst, T.3    González, J.G.4    Atisso, C.5    Sealls, W.6    Fahrbach, J.L.7
  • 32
    • 0141999599 scopus 로고    scopus 로고
    • Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects
    • Edwards, C.M., Todd, J.F., Ghatei, M.A., Bloom, S.R., Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects. Clin. Sci. 95 (1998), 719–724.
    • (1998) Clin. Sci. , vol.95 , pp. 719-724
    • Edwards, C.M.1    Todd, J.F.2    Ghatei, M.A.3    Bloom, S.R.4
  • 34
    • 84928314796 scopus 로고    scopus 로고
    • Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes—a randomized, single-blinded, cross-over pilot study
    • Faber, R., Zander, M., Pena, A., Michelsen, M.M., Mygind, N.D., Prescott, E., Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes—a randomized, single-blinded, cross-over pilot study. Cardiovasc. Diabetol., 14, 2015, 41.
    • (2015) Cardiovasc. Diabetol. , vol.14 , pp. 41
    • Faber, R.1    Zander, M.2    Pena, A.3    Michelsen, M.M.4    Mygind, N.D.5    Prescott, E.6
  • 35
    • 84914666192 scopus 로고    scopus 로고
    • Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus
    • Ferdinand, K.C., White, W.B., Calhoun, D.A., Lonn, E.M., Sager, P.T., Brunelle, R., Jiang, H.H., Threlkeld, R.J., Robertson, K.E., Geiger, M.J., Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension 64 (2014), 731–737.
    • (2014) Hypertension , vol.64 , pp. 731-737
    • Ferdinand, K.C.1    White, W.B.2    Calhoun, D.A.3    Lonn, E.M.4    Sager, P.T.5    Brunelle, R.6    Jiang, H.H.7    Threlkeld, R.J.8    Robertson, K.E.9    Geiger, M.J.10
  • 38
    • 84971350162 scopus 로고    scopus 로고
    • Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk
    • FLAT-SUGAR Trial Investigators. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk. Diabetes Care 39 (2016), 973–981, 10.2337/dc15-2782.
    • (2016) Diabetes Care , vol.39 , pp. 973-981
  • 41
    • 84903807727 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism
    • Goodwill, A.G., Tune, J.D., Noblet, J.N., Conteh, A.M., Sassoon, D., Casalini, E.D., Mather, K.J., Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism. Basic Res. Cardiol., 109, 2014, 426.
    • (2014) Basic Res. Cardiol. , vol.109 , pp. 426
    • Goodwill, A.G.1    Tune, J.D.2    Noblet, J.N.3    Conteh, A.M.4    Sassoon, D.5    Casalini, E.D.6    Mather, K.J.7
  • 42
    • 84958620086 scopus 로고    scopus 로고
    • Enteroendocrine cells: chemosensors in the intestinal epithelium
    • Gribble, F.M., Reimann, F., Enteroendocrine cells: chemosensors in the intestinal epithelium. Annu. Rev. Physiol. 78 (2016), 277–299.
    • (2016) Annu. Rev. Physiol. , vol.78 , pp. 277-299
    • Gribble, F.M.1    Reimann, F.2
  • 44
    • 77949268923 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells
    • Hadjiyanni, I., Siminovitch, K.A., Danska, J.S., Drucker, D.J., Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia 53 (2010), 730–740.
    • (2010) Diabetologia , vol.53 , pp. 730-740
    • Hadjiyanni, I.1    Siminovitch, K.A.2    Danska, J.S.3    Drucker, D.J.4
  • 46
    • 84880147886 scopus 로고    scopus 로고
    • Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes
    • He, L., Wong, C.K., Cheung, K.K., Yau, H.C., Fu, A., Zhao, H.L., Leung, K.M., Kong, A.P., Wong, G.W., Chan, P.K., et al. Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes. J. Diabetes Investig. 4 (2013), 382–392.
    • (2013) J. Diabetes Investig. , vol.4 , pp. 382-392
    • He, L.1    Wong, C.K.2    Cheung, K.K.3    Yau, H.C.4    Fu, A.5    Zhao, H.L.6    Leung, K.M.7    Kong, A.P.8    Wong, G.W.9    Chan, P.K.10
  • 47
    • 84885300888 scopus 로고    scopus 로고
    • Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial
    • Hermansen, K., Bækdal, T.A., Düring, M., Pietraszek, A., Mortensen, L.S., Jørgensen, H., Flint, A., Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes. Metab. 15 (2013), 1040–1048.
    • (2013) Diabetes Obes. Metab. , vol.15 , pp. 1040-1048
    • Hermansen, K.1    Bækdal, T.A.2    Düring, M.3    Pietraszek, A.4    Mortensen, L.S.5    Jørgensen, H.6    Flint, A.7
  • 48
    • 80054681735 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis
    • Hogan, A.E., Tobin, A.M., Ahern, T., Corrigan, M.A., Gaoatswe, G., Jackson, R., O'Reilly, V., Lynch, L., Doherty, D.G., Moynagh, P.N., et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia 54 (2011), 2745–2754.
    • (2011) Diabetologia , vol.54 , pp. 2745-2754
    • Hogan, A.E.1    Tobin, A.M.2    Ahern, T.3    Corrigan, M.A.4    Gaoatswe, G.5    Jackson, R.6    O'Reilly, V.7    Lynch, L.8    Doherty, D.G.9    Moynagh, P.N.10
  • 49
    • 84896080822 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus
    • Hogan, A.E., Gaoatswe, G., Lynch, L., Corrigan, M.A., Woods, C., O'Connell, J., O'Shea, D., Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia 57 (2014), 781–784.
    • (2014) Diabetologia , vol.57 , pp. 781-784
    • Hogan, A.E.1    Gaoatswe, G.2    Lynch, L.3    Corrigan, M.A.4    Woods, C.5    O'Connell, J.6    O'Shea, D.7
  • 50
    • 84901768284 scopus 로고    scopus 로고
    • Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
    • Holman, R.R., Sourij, H., Califf, R.M., Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 383 (2014), 2008–2017.
    • (2014) Lancet , vol.383 , pp. 2008-2017
    • Holman, R.R.1    Sourij, H.2    Califf, R.M.3
  • 51
    • 84953261551 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP
    • Hou, Y., Ernst, S.A., Heidenreich, K., Williams, J.A., Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP. Am. J. Physiol. Gastrointest. Liver Physiol. 310 (2016), G26–G33.
    • (2016) Am. J. Physiol. Gastrointest. Liver Physiol. , vol.310 , pp. G26-G33
    • Hou, Y.1    Ernst, S.A.2    Heidenreich, K.3    Williams, J.A.4
  • 52
    • 77949273334 scopus 로고    scopus 로고
    • The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
    • Hsieh, J., Longuet, C., Baker, C.L., Qin, B., Federico, L.M., Drucker, D.J., Adeli, K., The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 53 (2010), 552–561.
    • (2010) Diabetologia , vol.53 , pp. 552-561
    • Hsieh, J.1    Longuet, C.2    Baker, C.L.3    Qin, B.4    Federico, L.M.5    Drucker, D.J.6    Adeli, K.7
  • 54
    • 79952932916 scopus 로고    scopus 로고
    • Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes
    • Jimenez-Solem, E., Rasmussen, M.H., Christensen, M., Knop, F.K., Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Curr. Opin. Mol. Ther. 12 (2010), 790–797.
    • (2010) Curr. Opin. Mol. Ther. , vol.12 , pp. 790-797
    • Jimenez-Solem, E.1    Rasmussen, M.H.2    Christensen, M.3    Knop, F.K.4
  • 55
    • 84901465015 scopus 로고    scopus 로고
    • A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study)
    • Jorsal, A., Wiggers, H., Holmager, P., Nilsson, B., Nielsen, R., Boesgaard, T.W., Kumme, A., Møller, J.E., Videbæk, L., Kistorp, C., et al. A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study). BMJ Open, 4, 2014, e004885.
    • (2014) BMJ Open , vol.4 , pp. e004885
    • Jorsal, A.1    Wiggers, H.2    Holmager, P.3    Nilsson, B.4    Nielsen, R.5    Boesgaard, T.W.6    Kumme, A.7    Møller, J.E.8    Videbæk, L.9    Kistorp, C.10
  • 57
  • 59
    • 84866701959 scopus 로고    scopus 로고
    • Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects
    • Keller, J., Trautmann, M.E., Haber, H., Tham, L.S., Hunt, T., Mace, K., Linnebjerg, H., Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul. Pept. 179 (2012), 77–83.
    • (2012) Regul. Pept. , vol.179 , pp. 77-83
    • Keller, J.1    Trautmann, M.E.2    Haber, H.3    Tham, L.S.4    Hunt, T.5    Mace, K.6    Linnebjerg, H.7
  • 60
    • 84861944029 scopus 로고    scopus 로고
    • Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial
    • Kelly, A.S., Bergenstal, R.M., Gonzalez-Campoy, J.M., Katz, H., Bank, A.J., Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc. Diabetol., 11, 2012, 64.
    • (2012) Cardiovasc. Diabetol. , vol.11 , pp. 64
    • Kelly, A.S.1    Bergenstal, R.M.2    Gonzalez-Campoy, J.M.3    Katz, H.4    Bank, A.J.5
  • 61
    • 84921931382 scopus 로고    scopus 로고
    • Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study
    • Khunti, K., Davies, M., Majeed, A., Thorsted, B.L., Wolden, M.L., Paul, S.K., Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care 38 (2015), 316–322.
    • (2015) Diabetes Care , vol.38 , pp. 316-322
    • Khunti, K.1    Davies, M.2    Majeed, A.3    Thorsted, B.L.4    Wolden, M.L.5    Paul, S.K.6
  • 62
    • 84877317750 scopus 로고    scopus 로고
    • GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure
    • Kim, M., Platt, M.J., Shibasaki, T., Quaggin, S.E., Backx, P.H., Seino, S., Simpson, J.A., Drucker, D.J., GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat. Med. 19 (2013), 567–575.
    • (2013) Nat. Med. , vol.19 , pp. 567-575
    • Kim, M.1    Platt, M.J.2    Shibasaki, T.3    Quaggin, S.E.4    Backx, P.H.5    Seino, S.6    Simpson, J.A.7    Drucker, D.J.8
  • 63
    • 70349120958 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice
    • Koehler, J.A., Baggio, L.L., Lamont, B.J., Ali, S., Drucker, D.J., Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 58 (2009), 2148–2161.
    • (2009) Diabetes , vol.58 , pp. 2148-2161
    • Koehler, J.A.1    Baggio, L.L.2    Lamont, B.J.3    Ali, S.4    Drucker, D.J.5
  • 66
    • 84949110416 scopus 로고    scopus 로고
    • Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans
    • Koska, J., Sands, M., Burciu, C., D'Souza, K.M., Raravikar, K., Liu, J., Truran, S., Franco, D.A., Schwartz, E.A., Schwenke, D.C., et al. Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans. Diabetes 64 (2015), 2624–2635.
    • (2015) Diabetes , vol.64 , pp. 2624-2635
    • Koska, J.1    Sands, M.2    Burciu, C.3    D'Souza, K.M.4    Raravikar, K.5    Liu, J.6    Truran, S.7    Franco, D.A.8    Schwartz, E.A.9    Schwenke, D.C.10
  • 67
    • 84901341959 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism
    • Krasner, N.M., Ido, Y., Ruderman, N.B., Cacicedo, J.M., Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS ONE, 9, 2014, e97554.
    • (2014) PLoS ONE , vol.9 , pp. e97554
    • Krasner, N.M.1    Ido, Y.2    Ruderman, N.B.3    Cacicedo, J.M.4
  • 69
    • 84957439021 scopus 로고    scopus 로고
    • Interleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism
    • Lebherz, C., Kahles, F., Piotrowski, K., Vogeser, M., Foldenauer, A.C., Nassau, K., Kilger, E., Marx, N., Parhofer, K.G., Lehrke, M., Interleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism. Cardiovasc. Diabetol., 15, 2016, 21.
    • (2016) Cardiovasc. Diabetol. , vol.15 , pp. 21
    • Lebherz, C.1    Kahles, F.2    Piotrowski, K.3    Vogeser, M.4    Foldenauer, A.C.5    Nassau, K.6    Kilger, E.7    Marx, N.8    Parhofer, K.G.9    Lehrke, M.10
  • 71
    • 84962068591 scopus 로고    scopus 로고
    • Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction
    • Published online March 25, 2016
    • Lepore, J.J., Olson, E., Demopoulos, L., Haws, T., Fang, Z., Barbour, A.M., Fossler, M., Davila-Roman, V.G., Russell, S.D., Gropler, R.J., Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC Heart Fail., 2016, 10.1016/j.jchf.2016.01.008 Published online March 25, 2016.
    • (2016) JACC Heart Fail.
    • Lepore, J.J.1    Olson, E.2    Demopoulos, L.3    Haws, T.4    Fang, Z.5    Barbour, A.M.6    Fossler, M.7    Davila-Roman, V.G.8    Russell, S.D.9    Gropler, R.J.10
  • 72
    • 84921961337 scopus 로고    scopus 로고
    • Inflammation and immunity in diseases of the arterial tree: players and layers
    • Libby, P., Hansson, G.K., Inflammation and immunity in diseases of the arterial tree: players and layers. Circ. Res. 116 (2015), 307–311.
    • (2015) Circ. Res. , vol.116 , pp. 307-311
    • Libby, P.1    Hansson, G.K.2
  • 74
    • 84903177155 scopus 로고    scopus 로고
    • Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study
    • Lønborg, J., Vejlstrup, N., Kelbæk, H., Nepper-Christensen, L., Jørgensen, E., Helqvist, S., Holmvang, L., Saunamäki, K., Bøtker, H.E., Kim, W.Y., et al. Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study. Diabetes 63 (2014), 2474–2485, 10.2337/db13-1849.
    • (2014) Diabetes , vol.63 , pp. 2474-2485
    • Lønborg, J.1    Vejlstrup, N.2    Kelbæk, H.3    Nepper-Christensen, L.4    Jørgensen, E.5    Helqvist, S.6    Holmvang, L.7    Saunamäki, K.8    Bøtker, H.E.9    Kim, W.Y.10
  • 75
    • 84920053430 scopus 로고    scopus 로고
    • Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes
    • Lovshin, J.A., Barnie, A., DeAlmeida, A., Logan, A., Zinman, B., Drucker, D.J., Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 38 (2015), 132–139.
    • (2015) Diabetes Care , vol.38 , pp. 132-139
    • Lovshin, J.A.1    Barnie, A.2    DeAlmeida, A.3    Logan, A.4    Zinman, B.5    Drucker, D.J.6
  • 77
    • 84907420900 scopus 로고    scopus 로고
    • GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study
    • Margulies, K.B., Anstrom, K.J., Hernandez, A.F., Redfield, M.M., Shah, M.R., Braunwald, E., Cappola, T.P., Heart Failure Clinical Research Network. GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. Circ Heart Fail 7 (2014), 673–679.
    • (2014) Circ Heart Fail , vol.7 , pp. 673-679
    • Margulies, K.B.1    Anstrom, K.J.2    Hernandez, A.F.3    Redfield, M.M.4    Shah, M.R.5    Braunwald, E.6    Cappola, T.P.7
  • 80
    • 84923165949 scopus 로고    scopus 로고
    • Pre-treatment with glucagon-like peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization
    • McCormick, L.M., Hoole, S.P., White, P.A., Read, P.A., Axell, R.G., Clarke, S.J., O'Sullivan, M., West, N.E., Dutka, D.P., Pre-treatment with glucagon-like peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization. JACC Cardiovasc. Interv. 8 (2015), 292–301.
    • (2015) JACC Cardiovasc. Interv. , vol.8 , pp. 292-301
    • McCormick, L.M.1    Hoole, S.P.2    White, P.A.3    Read, P.A.4    Axell, R.G.5    Clarke, S.J.6    O'Sullivan, M.7    West, N.E.8    Dutka, D.P.9
  • 81
    • 84870054636 scopus 로고    scopus 로고
    • GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
    • Meier, J.J., GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8 (2012), 728–742.
    • (2012) Nat. Rev. Endocrinol. , vol.8 , pp. 728-742
    • Meier, J.J.1
  • 82
    • 84903519951 scopus 로고    scopus 로고
    • Risk of pancreatitis in patients treated with incretin-based therapies
    • Meier, J.J., Nauck, M.A., Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia 57 (2014), 1320–1324.
    • (2014) Diabetologia , vol.57 , pp. 1320-1324
    • Meier, J.J.1    Nauck, M.A.2
  • 83
    • 84942374717 scopus 로고    scopus 로고
    • Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial
    • Meier, J.J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.V., Menge, B.A., Forst, T., Kapitza, C., Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care 38 (2015), 1263–1273.
    • (2015) Diabetes Care , vol.38 , pp. 1263-1273
    • Meier, J.J.1    Rosenstock, J.2    Hincelin-Méry, A.3    Roy-Duval, C.4    Delfolie, A.5    Coester, H.V.6    Menge, B.A.7    Forst, T.8    Kapitza, C.9
  • 84
    • 84920095184 scopus 로고    scopus 로고
    • Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors
    • Mulvihill, E.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr. Rev. 35 (2014), 992–1019.
    • (2014) Endocr. Rev. , vol.35 , pp. 992-1019
    • Mulvihill, E.E.1    Drucker, D.J.2
  • 85
    • 84962388454 scopus 로고    scopus 로고
    • Inhibition of dipeptidyl peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat-fed diabetic mice
    • Mulvihill, E.E., Varin, E.M., Ussher, J.R., Campbell, J.E., Bang, K.W., Abdullah, T., Baggio, L.L., Drucker, D.J., Inhibition of dipeptidyl peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat-fed diabetic mice. Diabetes 65 (2016), 742–754.
    • (2016) Diabetes , vol.65 , pp. 742-754
    • Mulvihill, E.E.1    Varin, E.M.2    Ussher, J.R.3    Campbell, J.E.4    Bang, K.W.5    Abdullah, T.6    Baggio, L.L.7    Drucker, D.J.8
  • 87
    • 84962097356 scopus 로고    scopus 로고
    • Effects of GLP-1 receptor agonists on heart rate and the autonomic nervous system using Holter electrocardiography and power spectrum analysis of heart rate variability
    • Nakatani, Y., Kawabe, A., Matsumura, M., Aso, Y., Yasu, T., Banba, N., Nakamoto, T., Effects of GLP-1 receptor agonists on heart rate and the autonomic nervous system using Holter electrocardiography and power spectrum analysis of heart rate variability. Diabetes Care 39 (2016), e22–e23.
    • (2016) Diabetes Care , vol.39 , pp. e22-e23
    • Nakatani, Y.1    Kawabe, A.2    Matsumura, M.3    Aso, Y.4    Yasu, T.5    Banba, N.6    Nakamoto, T.7
  • 89
    • 84893055427 scopus 로고    scopus 로고
    • Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: involvement of the GLP-1 pathway
    • Nguyen, A.T., Mandard, S., Dray, C., Deckert, V., Valet, P., Besnard, P., Drucker, D.J., Lagrost, L., Grober, J., Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: involvement of the GLP-1 pathway. Diabetes 63 (2014), 471–482.
    • (2014) Diabetes , vol.63 , pp. 471-482
    • Nguyen, A.T.1    Mandard, S.2    Dray, C.3    Deckert, V.4    Valet, P.5    Besnard, P.6    Drucker, D.J.7    Lagrost, L.8    Grober, J.9
  • 91
    • 1442311383 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
    • Nikolaidis, L.A., Mankad, S., Sokos, G.G., Miske, G., Shah, A., Elahi, D., Shannon, R.P., Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004), 962–965.
    • (2004) Circulation , vol.109 , pp. 962-965
    • Nikolaidis, L.A.1    Mankad, S.2    Sokos, G.G.3    Miske, G.4    Shah, A.5    Elahi, D.6    Shannon, R.P.7
  • 92
    • 28144441354 scopus 로고    scopus 로고
    • Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
    • Nikolaidis, L.A., Elahi, D., Shen, Y.T., Shannon, R.P., Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 289 (2005), H2401–H2408.
    • (2005) Am. J. Physiol. Heart Circ. Physiol. , vol.289 , pp. H2401-H2408
    • Nikolaidis, L.A.1    Elahi, D.2    Shen, Y.T.3    Shannon, R.P.4
  • 93
    • 84942673427 scopus 로고    scopus 로고
    • A Comparison of the Effects of the GLP-1 analogue liraglutide and insulin glargine on endothelial function and metabolic parameters: a randomized, controlled trial sapporo athero-incretin study 2 (SAIS2)
    • Nomoto, H., Miyoshi, H., Furumoto, T., Oba, K., Tsutsui, H., Miyoshi, A., Kondo, T., Tsuchida, K., Atsumi, T., Manda, N., et al., SAIS Study Group. A Comparison of the Effects of the GLP-1 analogue liraglutide and insulin glargine on endothelial function and metabolic parameters: a randomized, controlled trial sapporo athero-incretin study 2 (SAIS2). PLoS ONE, 10, 2015, e0135854.
    • (2015) PLoS ONE , vol.10 , pp. e0135854
    • Nomoto, H.1    Miyoshi, H.2    Furumoto, T.3    Oba, K.4    Tsutsui, H.5    Miyoshi, A.6    Kondo, T.7    Tsuchida, K.8    Atsumi, T.9    Manda, N.10
  • 99
    • 84959555725 scopus 로고    scopus 로고
    • Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database
    • Pizzimenti, V., Giandalia, A., Cucinotta, D., Russo, G.T., Smits, M., Cutroneo, P.M., Trifirò, G., Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database. J. Clin. Pharm. Ther. 41 (2016), 116–118.
    • (2016) J. Clin. Pharm. Ther. , vol.41 , pp. 116-118
    • Pizzimenti, V.1    Giandalia, A.2    Cucinotta, D.3    Russo, G.T.4    Smits, M.5    Cutroneo, P.M.6    Trifirò, G.7
  • 100
    • 84871675071 scopus 로고    scopus 로고
    • The glucagon-like peptide-1 receptor—or not?
    • Pyke, C., Knudsen, L.B., The glucagon-like peptide-1 receptor—or not?. Endocrinology 154 (2013), 4–8.
    • (2013) Endocrinology , vol.154 , pp. 4-8
    • Pyke, C.1    Knudsen, L.B.2
  • 102
    • 84860390563 scopus 로고    scopus 로고
    • A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans
    • Read, P.A., Hoole, S.P., White, P.A., Khan, F.Z., O'Sullivan, M., West, N.E., Dutka, D.P., A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ. Cardiovasc. Interv. 4 (2011), 266–272.
    • (2011) Circ. Cardiovasc. Interv. , vol.4 , pp. 266-272
    • Read, P.A.1    Hoole, S.P.2    White, P.A.3    Khan, F.Z.4    O'Sullivan, M.5    West, N.E.6    Dutka, D.P.7
  • 103
    • 84857111888 scopus 로고    scopus 로고
    • Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease
    • Read, P.A., Khan, F.Z., Dutka, D.P., Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart 98 (2012), 408–413.
    • (2012) Heart , vol.98 , pp. 408-413
    • Read, P.A.1    Khan, F.Z.2    Dutka, D.P.3
  • 105
    • 84867136387 scopus 로고    scopus 로고
    • Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice
    • Rieg, T., Gerasimova, M., Murray, F., Masuda, T., Tang, T., Rose, M., Drucker, D.J., Vallon, V., Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am. J. Physiol. Renal Physiol. 303 (2012), F963–F971.
    • (2012) Am. J. Physiol. Renal Physiol. , vol.303 , pp. F963-F971
    • Rieg, T.1    Gerasimova, M.2    Murray, F.3    Masuda, T.4    Tang, T.5    Rose, M.6    Drucker, D.J.7    Vallon, V.8
  • 107
    • 84926648779 scopus 로고    scopus 로고
    • Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease
    • Sandoval, D.A., D'Alessio, D.A., Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol. Rev. 95 (2015), 513–548.
    • (2015) Physiol. Rev. , vol.95 , pp. 513-548
    • Sandoval, D.A.1    D'Alessio, D.A.2
  • 108
    • 84973167573 scopus 로고    scopus 로고
    • A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
    • Scott, R.A., Freitag, D.F., Li, L., Chu, A.Y., Surendran, P., Young, R., Grarup, N., Stancáková, A., Chen, Y., Varga, T.V., et al. CVD50 consortium GERAD_EC Consortium Neurology Working Group of the Cohorts for Heart Aging Research in Genomic Epidemiology (CHARGE) Alzheimer's Disease Genetics Consortium Pancreatic Cancer Cohort Consortium European Prospective Investigation into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) EPIC-InterAct CHARGE consortium CHD Exome+ Consortium, CARDIOGRAM Exome Consortium. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Sci. Transl. Med., 8, 2016, 341ra76, 10.1126/scitranslmed.aad3744.
    • (2016) Sci. Transl. Med. , vol.8 , pp. 341ra76
    • Scott, R.A.1    Freitag, D.F.2    Li, L.3    Chu, A.Y.4    Surendran, P.5    Young, R.6    Grarup, N.7    Stancáková, A.8    Chen, Y.9    Varga, T.V.10
  • 111
    • 84940751369 scopus 로고    scopus 로고
    • Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
    • Simó, R., Guerci, B., Schernthaner, G., Gallwitz, B., Rosas-Guzmàn, J., Dotta, F., Festa, A., Zhou, M., Kiljański, J., Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovasc. Diabetol., 14, 2015, 116.
    • (2015) Cardiovasc. Diabetol. , vol.14 , pp. 116
    • Simó, R.1    Guerci, B.2    Schernthaner, G.3    Gallwitz, B.4    Rosas-Guzmàn, J.5    Dotta, F.6    Festa, A.7    Zhou, M.8    Kiljański, J.9
  • 113
    • 33845293219 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
    • Sokos, G.G., Nikolaidis, L.A., Mankad, S., Elahi, D., Shannon, R.P., Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail. 12 (2006), 694–699.
    • (2006) J. Card. Fail. , vol.12 , pp. 694-699
    • Sokos, G.G.1    Nikolaidis, L.A.2    Mankad, S.3    Elahi, D.4    Shannon, R.P.5
  • 114
    • 84990057324 scopus 로고    scopus 로고
    • Glucose-dependent insulinotropic peptide stimulates glucagon-like peptide 1 production by pancreatic islets via interleukin 6, produced by α cells
    • Published online March 10, 2016
    • Timper, K., Dalmas, E., Dror, E., Rütti, S., Thienel, C., Sauter, N.S., Bouzakri, K., Bédat, B., Pattou, F., Kerr-Conte, J., et al. Glucose-dependent insulinotropic peptide stimulates glucagon-like peptide 1 production by pancreatic islets via interleukin 6, produced by α cells. Gastroenterology, 2016, 10.1053/j.gastro.2016.03.003 Published online March 10, 2016.
    • (2016) Gastroenterology
    • Timper, K.1    Dalmas, E.2    Dror, E.3    Rütti, S.4    Thienel, C.5    Sauter, N.S.6    Bouzakri, K.7    Bédat, B.8    Pattou, F.9    Kerr-Conte, J.10
  • 115
    • 84860204551 scopus 로고    scopus 로고
    • Cardiovascular biology of the incretin system
    • Ussher, J.R., Drucker, D.J., Cardiovascular biology of the incretin system. Endocr. Rev. 33 (2012), 187–215.
    • (2012) Endocr. Rev. , vol.33 , pp. 187-215
    • Ussher, J.R.1    Drucker, D.J.2
  • 116
    • 84901462249 scopus 로고    scopus 로고
    • Cardiovascular actions of incretin-based therapies
    • Ussher, J.R., Drucker, D.J., Cardiovascular actions of incretin-based therapies. Circ. Res. 114 (2014), 1788–1803.
    • (2014) Circ. Res. , vol.114 , pp. 1788-1803
    • Ussher, J.R.1    Drucker, D.J.2
  • 118
    • 84922572669 scopus 로고    scopus 로고
    • Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment
    • von Scholten, B.J., Lajer, M., Goetze, J.P., Persson, F., Rossing, P., Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diabet. Med. 32 (2015), 343–352.
    • (2015) Diabet. Med. , vol.32 , pp. 343-352
    • von Scholten, B.J.1    Lajer, M.2    Goetze, J.P.3    Persson, F.4    Rossing, P.5
  • 120
    • 84938414413 scopus 로고    scopus 로고
    • Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas
    • Waser, B., Blank, A., Karamitopoulou, E., Perren, A., Reubi, J.C., Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas. Mod. Pathol. 28 (2015), 391–402.
    • (2015) Mod. Pathol. , vol.28 , pp. 391-402
    • Waser, B.1    Blank, A.2    Karamitopoulou, E.3    Perren, A.4    Reubi, J.C.5
  • 122
    • 84954571387 scopus 로고    scopus 로고
    • Cardiovascular effects of incretin-based therapies
    • White, W.B., Baker, W.L., Cardiovascular effects of incretin-based therapies. Annu. Rev. Med. 67 (2016), 245–260.
    • (2016) Annu. Rev. Med. , vol.67 , pp. 245-260
    • White, W.B.1    Baker, W.L.2
  • 123
    • 84960810832 scopus 로고    scopus 로고
    • The intestinal immune system in obesity and insulin resistance
    • Winer, D.A., Luck, H., Tsai, S., Winer, S., The intestinal immune system in obesity and insulin resistance. Cell Metab. 23 (2016), 413–426.
    • (2016) Cell Metab. , vol.23 , pp. 413-426
    • Winer, D.A.1    Luck, H.2    Tsai, S.3    Winer, S.4
  • 125
    • 84883295202 scopus 로고    scopus 로고
    • Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study
    • Woo, J.S., Kim, W., Ha, S.J., Kim, J.B., Kim, S.J., Kim, W.S., Seon, H.J., Kim, K.S., Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler. Thromb. Vasc. Biol. 33 (2013), 2252–2260.
    • (2013) Arterioscler. Thromb. Vasc. Biol. , vol.33 , pp. 2252-2260
    • Woo, J.S.1    Kim, W.2    Ha, S.J.3    Kim, J.B.4    Kim, S.J.5    Kim, W.S.6    Seon, H.J.7    Kim, K.S.8
  • 126
    • 84861528676 scopus 로고    scopus 로고
    • Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans
    • Xiao, C., Bandsma, R.H., Dash, S., Szeto, L., Lewis, G.F., Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler. Thromb. Vasc. Biol. 32 (2012), 1513–1519.
    • (2012) Arterioscler. Thromb. Vasc. Biol. , vol.32 , pp. 1513-1519
    • Xiao, C.1    Bandsma, R.H.2    Dash, S.3    Szeto, L.4    Lewis, G.F.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.